|
Q1 FY2027
As of Jul 31, 2026
|
Q4 FY2026
As of Apr 30, 2026
|
Q3 FY2026
As of Jan 31, 2026
|
Q2 FY2026
As of Oct 31, 2025
|
Q1 FY2026
As of Jul 31, 2025
|
Q4 FY2025
As of Apr 30, 2025
|
Q3 FY2025
As of Jan 31, 2025
|
Q2 FY2025
As of Oct 31, 2024
|
Q1 FY2025
As of Jul 31, 2024
|
Q4 FY2024
As of Apr 30, 2024
|
Q3 FY2024
As of Jan 31, 2024
|
Q2 FY2024
As of Oct 31, 2023
|
Q1 FY2024
As of Jul 31, 2023
|
Q4 FY2023
As of Apr 30, 2023
|
Q3 FY2023
As of Jan 31, 2023
|
Q2 FY2023
As of Oct 31, 2022
|
Q1 FY2023
As of Jul 31, 2022
|
Q4 FY2022
As of Apr 30, 2022
|
Q3 FY2022
As of Jan 31, 2022
|
Q2 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Restricted cash, short-term | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Contract assets | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||||||
| Restricted cash, long-term | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Earn out payable | ||||||||||||||||||||
| Convertible notes payable (Note 13) | ||||||||||||||||||||
| Derivative liability (Note 13) | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Contract liabilities, current | ||||||||||||||||||||
| Right-of-use liabilities, current portion | ||||||||||||||||||||
| Contingent liabilities, current portion | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Right-of-use liabilities, less current portion | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ Equity: | ||||||||||||||||||||
| Common stock, $0.001 par value; authorized 400,000,000 shares, issued 9,094,159 shares and 7,704,867 shares, respectively; outstanding 9,004,628 shares and 7,615,336 shares, respectively | ||||||||||||||||||||
| Treasury stock, at cost; 89,531 and 89,531 shares, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
